AlzeCure Pharma
AlzeCure publishes new disease modifying data with NeuroRestore ACD856 against Alzheimer’s and cognitive disorders
AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that a new scientific article has been published on NeuroRestore ACD856 and preclinical results supporting its disease-modifying effect.
The article, titled "Neuroprotective and disease modifying effects of the triazinetrione ACD856, a positive allosteric modulator of Trk-receptors for the treatment of cognitive dysfunction in Alzheimer’s disease", is published in the International Journal of Molecular Sciences and is written by Pontus Forsell, Head of Research and Discovery. Co-authors are Cristina Parrado-Fernandez, Sanja Juric, Maria Backlund, Märta Dahlström, Nather Madjid, Veronica Lidell, Azita Rasti, Johan Sandin and Gunnar Nordvall.
The article focuses on the characterization of ACD856, the leading clinical drug candidate in the NeuroRestore platform which, being a Trk-PAM, increases BDNF and NGF signaling. ACD856 was tested in various preclinical models to investigate its potential disease-modifying effects. The results show that ACD856 has positive effects on neurite outgrowth, has protective effects against amyloid-beta induced nerve damage and has positive effects on the synapses – the contact surfaces between nerve cells where the exchange of information takes place.
"The data presented in the article add a substantial amount of information to our growing body of evidence strongly indicating that ACD856 could both have disease modifying and symptomatic effects in Alzheimer’s disease. We are encouraged by the compelling multimodal results with ACD856 demonstrating significant protection against amyloid-beta induced neurotoxicity, enhanced neurite outgrowth and increased levels of BDNF, both in vitro and in vivo in aged animals. Apart from being a stand-alone treatment, the recent findings also enhance the possibilities for ACD856 as a future combination treatment with anti-amyloid antibodies, such as Leqembi (lecanemab)," said Pontus Forsell, Head of Research and Discovery at AlzeCure Pharma.
“There is major international scientific interest in new therapeutic mechanisms in Alzheimer's and other neurodegenerative diseases. Neurotrophins are a very interesting area with potential for multiple indications, not only Alzheimer's. Depression and Parkinson's are also diseases where this mechanism has scientific support," said Martin Jönsson, CEO of AlzeCure Pharma AB. ”These new results with ACD856 significantly strengthen the commercial potential of the project, which we now prepare for phase II studies.”
The article is available via the following link:
https://www.mdpi.com/1422-0067/24/13/11159
Datum | 2023-07-11, kl 08:00 |
Källa | MFN |
AlzeCure publishes new disease modifying data with NeuroRestore ACD856 against Alzheimer’s and cognitive disorders | |
Martin Och Pontus |
![](https://static.allaaktier.se/ads/hand-waving-2.png)